Analyst Ratings February 6, 2026

D. Boral Capital Lowers CollPlant Rating to Hold After Financing and Revenue Miss

Analyst downgrades follow a sharp share decline, a small registered direct offering and a substantial shortfall in third-quarter revenue

By Jordan Park CLGN
D. Boral Capital Lowers CollPlant Rating to Hold After Financing and Revenue Miss
CLGN

D. Boral Capital downgraded CollPlant Holdings Inc. (NASDAQ:CLGN) from Buy to Hold on Friday, citing the company’s recently announced $2.0 million registered direct financing and a material gap between reported third-quarter revenue and analyst expectations. The downgrade comes as the stock has plunged 60.32% over the prior week, trading at $0.75 and hovering near a 52-week low of $0.66.

Key Points

  • D. Boral Capital downgraded CollPlant from Buy to Hold, citing the company's $2.0 million registered direct financing as the primary reason.
  • CollPlant's shares dropped 60.32% over the past week and were trading at $0.75, near a 52-week low of $0.66.
  • The company reported third-quarter revenue of $77,000, well below the analyst consensus estimate of $2.76 million.

D. Boral Capital shifted its recommendation on CollPlant Holdings Inc. (NASDAQ:CLGN) from Buy to Hold on Friday, pointing to a string of company disclosures that, in the firm's view, justify a more cautious stance.

The research house flagged CollPlant’s recently announced $2.0 million registered direct financing as the principal catalyst for the rating change. While the amount raised is modest, D. Boral Capital emphasized the market’s unusually adverse reaction to the announcement and questioned why such a limited capital extension produced a disproportionately negative move in the share price.

Market moves were sharp: shares have fallen 60.32% over the past week and were trading at $0.75 at the time of the downgrade, near the 52-week low of $0.66. According to the research firm, the episode illustrates how a difficult capital environment can influence issuer behavior - in this case, CollPlant’s apparent decision to accept the financing terms available amid current conditions.

D. Boral Capital warned that this dynamic - accepting modest financing under strained market conditions - may erode investor confidence and could start a self-reinforcing downward cycle in the company’s valuation if sentiment continues to deteriorate.

In a separate but related disclosure, CollPlant Biotechnologies reported third-quarter revenue of $77,000, a result that fell well short of the analyst consensus estimate of $2.76 million. The gap between reported revenue and expectations was highlighted by the research firm as a key development, underscoring a significant divergence between actual performance and the market’s prior assumptions.

Those results provide stakeholders with clearer information on the company’s current financial position. The pronounced revenue shortfall, D. Boral Capital suggested, may prompt analysts and investors to re-evaluate their forward-looking assessments of CollPlant’s performance. More broadly, the firm noted that earnings and revenue disclosures remain central to how market participants judge operational efficiency and competitive standing.


Contextual note: The observations and rating change reflect D. Boral Capital’s interpretation of the company’s financing choice and recent financial results, as described above.

Risks

  • Market reaction risk: The sharp fall in share price following a modest $2.0 million financing highlights the potential for outsized market moves that can affect investor confidence - impacting equity markets and investor sentiment in small-cap biotech.
  • Operational and financial performance risk: A significant shortfall between reported revenue ($77,000) and expectations ($2.76 million) raises uncertainty about near-term financial health and may trigger reassessments by analysts and investors - relevant to the biotech and healthcare sectors.
  • Capital environment risk: Continued difficult capital markets could pressure companies to accept financing terms that may be viewed negatively by the market, potentially amplifying valuation declines - affecting capital markets and small-cap issuers.

More from Analyst Ratings

Stifel Lowers JFrog Target Citing AI-Driven Security Concerns; Maintains Buy Rating Feb 22, 2026 HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026